Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 4/20 | 0.55 |
| ▸ | KIT | P10721 | 3/20 | 0.55 |
| ▸ | BRAF | P15056 | 9/20 | 0.54 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | TEK | Q02763 | 1/20 | 0.49 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 3/20 | 0.49 |
| ▸ | BTK | Q06187 | 3/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL544729 | 0.90 | BRAF (0.60) | CSF1RKITBRAFKDRTEK | |
| SCHEMBL543733 | 0.83 | BRAF (0.66) | CSF1RKITBRAFKDRTEK | |
| SCHEMBL544048 | 0.82 | MAPK14 (0.46) | KDRMAPK14 | |
| SCHEMBL543846 | 0.80 | MAPT (0.51) | KITKDRTEKLCKBTK | |
| SCHEMBL3303142 | 0.79 | FLT1 (0.42) | KDRMAPK14 | |
| SCHEMBL544012 | 0.78 | FASN (0.51) | KITBRAFKDRTEK | |
| SCHEMBL2339289 | 0.78 | FLT1 (0.50) | KDRMAPK14MAPT | |
| SCHEMBL544249 | 0.76 | BRAF (0.56) | CSF1RKITBRAFKDRTEK | |
| SCHEMBL543756 | 0.75 | CSF1R (0.59) | CSF1RKITBRAFTEKPIKFYVE | |
| SCHEMBL544076 | 0.75 | ABL1 (0.62) | CSF1RBRAFKDRPIKFYVEPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207572-A1 | Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma | AB SCIENCE | 2008-08-28 | — | — | US | claimed |
| EP-2117531-B1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2016-11-02 | — | — | EP | disclosed |
| EP-2117531-B1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2016-11-02 | — | — | EP | disclosed |
| US-8227470-B2 | Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors | AB SCIENCE (FR) | 2012-07-24 | — | — | US | disclosed |
| US-8227470-B2 | Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors | AB SCIENCE (FR) | 2012-07-24 | — | — | US | disclosed |
| US-20100093750-A1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB SCIENCE | 2010-04-15 | — | — | US | disclosed |
| US-20100093750-A1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB SCIENCE | 2010-04-15 | — | — | US | disclosed |
| EP-2117531-A1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB Science (FR) | 2009-11-18 | — | — | EP | disclosed |
| US-20080207572-A1 | Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma | AB SCIENCE | 2008-08-28 | — | — | US | disclosed |
| US-20080207572-A1 | Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma | AB SCIENCE | 2008-08-28 | — | — | US | disclosed |
| WO-2008084103-A1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008084103-A1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2008-07-17 | — | — | WO | disclosed |
| WO-2007026251-A2 | USE OF DUAL C-KIT/FGFR3 INHIBITORS FOR TREATING MULTIPLE MYELOMA | AB SCIENCE (FR) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207572-A1 | Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma | KIT, FGFR3, AURKC | CSF1R 229/4885KIT 1/4885BRAF 710/4885 |
| US-20100093750-A1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | ERBB2, ERBB3, ERBB4 | CSF1R 1146/4885KIT 2283/4885BRAF 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.